The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Antiviral Chemistry & Chemotherapy

• Publication date

  2012-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3851/IMP2125PMID 22592135PMCID PMC6271563
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

  2012cited by this paper
• Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.

  2012cited by this paper
• Treatment of chronic hepatitis C – are interferons really necessary?

  2012cited by this paper
• Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta‐analysis

  2012cited by this paper
• Preliminary study of two antiviral agents for hepatitis C genotype 1.

  2012cited by this paper
• An orally available, small-molecule interferon inhibits viral replication

  2012cited by this paper
• Update on alisporivir in treatment of viral hepatitis C

  2012cited by this paper
• Management of Hepatitis C in Patients with Chronic Kidney Disease

  2012cited by this paper
• Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7

  2012cited by this paper
• The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C

  2012cited by this paper
• Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C

  2012cited by this paper
• Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents

  2012cited by this paper
• Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C

  2011cited by this paper
• Evolving epidemiology of hepatitis C virus.

  2011cited by this paper
• Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

  2011influential reference
• S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.

  2011cited by this paper
• Ribavirin potentiates interferon action by augmenting interferon‐stimulated gene induction in hepatitis C virus cell culture models

  2011cited by this paper
• Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Negative Regulation of Interferon-β Gene Expression during Acute and Persistent Virus Infections

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Selection of hepatitis C virus resistant to ribavirin

  2011cited by this paper
• Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease

  2011cited by this paper
• Second-wave protease inhibitors: choosing an heir.

  2011cited by this paper
• Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

  2010influential reference
• Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.

  2010cited by this paper
• ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

  2010cited by this paper
• Role of ribavirin in HCV treatment response: now and in the future

  2010cited by this paper
• The next step for taribavirin

  2010cited by this paper
• Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.

  2010cited by this paper
• Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

  2010cited by this paper
• Characterization of ribavirin uptake systems in human hepatocytes.

  2010cited by this paper
• Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response

  2010cited by this paper
• Ribavirin improves early responses to peginterferon through improved interferon signaling.

  2010cited by this paper
• Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.

  2010cited by this paper
• The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

  2010cited by this paper
• Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

  2010cited by this paper
• Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

  2010cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009influential reference
• Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

  2009cited by this paper
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

  2009influential reference
• Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities

  2009cited by this paper
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

  2009cited by this paper
• Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

  2009cited by this paper
• Hepatitis C: Current options for nonresponders to peginterferon and ribavirin

  2008cited by this paper
• Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment

  2008cited by this paper
• Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV

  2008cited by this paper
• Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

  2008cited by this paper
• Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters.

  2007cited by this paper
• Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.

  2007influential reference
• Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

  2007cited by this paper
• Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy

  2007cited by this paper
• Quasispecies and its impact on viral hepatitis

  2007cited by this paper
• Structural effects on the phosphorylation of 3-substituted 1-β-d-ribofuranosyl-1,2,4-triazoles by human adenosine kinase

  2007cited by this paper
• A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.

  2007cited by this paper
• Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.

  2007cited by this paper
• Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

  2007cited by this paper
• Interferons at age 50: past, current and future impact on biomedicine

  2007cited by this paper
• Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

  2006cited by this paper
• Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials

  2006cited by this paper
• Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

  2006cited by this paper
• Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon α‐2b and ribavirin combination after liver transplantation

  2006cited by this paper
• The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

  2006cited by this paper
• Nucleoside transporters: from scavengers to novel therapeutic targets.

  2006cited by this paper
• High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C

  2005cited by this paper
• Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin.

  2005cited by this paper
• Immunology of hepatitis B virus and hepatitis C virus infection

  2005cited by this paper
• A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.

  2005cited by this paper
• Metabolism and antiviral activity of ribavirin.

  2005cited by this paper
• Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

  2005cited by this paper
• Ribavirin Resistance in Hepatitis C Virus Replicon-Containing Cell Lines Conferred by Changes in the Cell Line or Mutations in the Replicon RNA

  2005cited by this paper
• Mechanism of action of interferon and ribavirin in treatment of hepatitis C

  2005cited by this paper
• HCV natural history: the retrospective and prospective in perspective.

  2005cited by this paper
• Antiviral action of ribavirin in chronic hepatitis C.

  2004cited by this paper
• Mammalian nucleoside transporters.

  2004cited by this paper
• The role of ribavirin in the combination therapy of hepatitis C virus infection.

  2004cited by this paper
• Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

  2004cited by this paper
• Effects of antiviral therapy on the cellular immune response in acute hepatitis C

  2004cited by this paper
• (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003influential reference
• Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase.

  2003cited by this paper
• Ribavirin Treatment Up-Regulates Antiviral Gene Expression via the Interferon-Stimulated Response Element in Respiratory Syncytial Virus-Infected Epithelial Cells

  2003cited by this paper
• Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

  2003cited by this paper
• The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

  2003cited by this paper
• Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

  2003cited by this paper
• Initial Binding of the Broad Spectrum Antiviral Nucleoside Ribavirin to the Hepatitis C Virus RNA Polymerase*

  2003cited by this paper
• Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

  2003cited by this paper
• Threshold for neutropenia in the adjustment of interferon treatment in HCV infection

  2003cited by this paper
• Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons

  2003cited by this paper
• Identification of a Ribavirin‐resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

  2003cited by this paper
• The Potentiating Effect of Ribavirin on Interferon in the Treatment of Hepatitis C: Lack of Evidence for Ribavirin-Induced Viral Mutagenesis

  2002cited by this paper
• Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• RNA virus error catastrophe: Direct molecular test by using ribavirin

  2001cited by this paper
• Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin*

  2001cited by this paper
• Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography.

  2000cited by this paper

• Emerging Host-Targeted Antivirals for Respiratory Viruses: Antivirals Targeting Virus Elements versus Host Mechanisms

  2026cites this paper
• Pan-viral efficacy profile of ribavirin: quantitative potency and safety landscape across virus families

  2025cites this paper
• Forced Degradation Study of Atazanavir, Emtricitabine, Nirmatrelvir, Oseltamivir, Ribavirin and Sofosbuvir

  2025cites this paper
• A medicinal chemistry overview of direct-acting antivirals approved in 2013-2024 by US FDA.

  2025cites this paper
• Synthesis and in vitro anti-diabetic activity of Triazole-enamide derivatives and inhibition of DPP-IV enzyme: An in silico approach

  2025cites this paper
• Novel and repurposed antiviral molecules for arbovirus infections with epidemic Potential: A systematic review

  2025cites this paper
• Advancements in antiviral approaches against foot-and-mouth disease virus: a comprehensive review

  2025cites this paper
• Effects of Thermal and Antibiotic Treatments on the Viral Accumulation of FcMV1 in Fusarium circinatum Isolates

  2025cites this paper
• Potential benefits of Nigella Sativa (black seeds) in the management of “Chandipura virus infection” – an insight

  2025cites this paper
• AMPK activation by hepatitis E virus infection inhibits viral replication through attenuation of autophagosomes and promotion of innate immunity

  2025cites this paper
• Thermal cycling-hyperthermia down-regulates liposaccharide-induced inflammation in human blood and helps with clearance of herpes simplex virus type 1

  2024cites this paper
• Assessment of virus eradication methods from infected in vitro-grown apricot cultures

  2024cites this paper
• An LSTM network-based model with attention techniques for predicting linear T-cell epitopes of the hepatitis C virus

  2024cites this paper
• Application of mPEG‐PCL‐mPEG Micelles for Anti‐Zika Ribavirin Delivery

  2024cites this paper
• N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses

  2024cites this paper
• Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis.

  2024cites this paper
• A review of recent advances in drug loading, mathematical modeling and applications of hydrogel drug delivery systems

  2024cites this paper
• Recent advances in triazole synthesis via click chemistry and their pharmacological applications: A review.

  2024cites this paper
• Design, Synthesis, and In-vitro anti-tuberculosis activity of 2-substituted-1,5-diphenyl-1,2-dihydro-3H-1,2,4-triazole-3-thione Derivatives

  2024cites this paper
• A Pharmacological Update of Triazole Derivative: A Review.

  2024cites this paper
• Exploring Triazole-Based Drugs: Synthesis, Application, FDA Approvals, and Clinical Trial Updates - A Comprehensive Review

  2024cites this paper
• Investigation of the embryo-toxicity of the antiviral drug “Ribavirin” in Wistar rats during different gestation periods

  2023cites this paper
• Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

  2023cites this paper
• The Potential Use of Polymeric Nanomaterials Against the Spread of the SARS-Cov-2 and its Variants: A Necessary Briefing

  2023cites this paper
• A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

  2023cites this paper
• Metabolomic analysis for disclosing nutritional and therapeutic prospective of traditional rice cultivars of Cauvery deltaic region, India

  2023cites this paper
• Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities

  2023cites this paper
• TROLLOPE: A novel sequence-based stacked approach for the accelerated discovery of linear T-cell epitopes of hepatitis C virus

  2023cites this paper
• Nano-fluorescent quantum dots as substrates for determination of ribavirin in pharmaceuticals and human plasma as well as monitoring of its kinetic interaction with salmon sperm DNA

  2023cites this paper
• An Overview of Mycoviral Curing Strategies Used in Evaluating Fungal Host Fitness

  2023cites this paper
• The Rhizopus Holobiont: A Model to Decipher Fungal-Bacterial-Viral Symbioses.

  2023cites this paper
• Discovery of non-nucleoside oxindole derivatives as potent inhibitors against dengue RNA-dependent RNA polymerase.

  2022cites this paper
• Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study

  2022cites this paper
• MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication

  2022cites this paper
• Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients

  2022influential citation
• Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity

  2022cites this paper
• A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania

  2022cites this paper
• SARS-CoV-2: una revisión rápida de algunas de las opciones de tratamiento disponibles.

  2022cites this paper
• Thermal cycling-hyperthermia down-regulates 1 liposaccharide-induced inflammatory response in human 2 whole-blood and helps clear herpes simplex virus type 1 by 3 U-937 macrophages

  2022cites this paper
• From hepatitis A to E: A critical review of viral hepatitis

  2021cites this paper
• Synthesis of new 1,2,4‐triazole–(thio)semicarbazide hybrid molecules: Their tyrosinase inhibitor activities and molecular docking analysis

  2021cites this paper
• Study the Effect of Sofosbuvir, Daclatasvir and Ribavirin on Hematologic Profile, ‎Vitamin B12 and Folic Acid Levels in HCV-Related Cirrhotic Patients‎

  2021cites this paper
• Environmental aspect and applications of nanotechnology to eliminate COVID-19 epidemiology risk

  2021cites this paper
• Hepatitis E Virus—Current Developments in Antiviral Strategies

  2021cites this paper
• 4′‐Selenonucleosides: Regio‐ and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti‐Hepatitis C Virus (HCV) Agents

  2021cites this paper
• Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Metabolic Modifications by Common Respiratory Viruses and Their Potential as New Antiviral Targets

  2021cites this paper
• Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2

  2021cites this paper
• Recent investigation on heterocycles with one nitrogen [piperidine, pyridine and quinoline], two nitrogen [1,3,4-thiadiazole and pyrazole] and three nitrogen [1,2,4-triazole]: a review

  2021cites this paper
• A Review on the Progress and Prospects of Dengue Drug Discovery Targeting NS5 RNA- Dependent RNA Polymerase.

  2020cites this paper
• Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy

  2020cites this paper
• Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder

  2020cites this paper
• A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study

  2020cites this paper
• IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.

  2020cites this paper
• Role of Genetic Variations in the Hepatic Handling of Drugs

  2020cites this paper
• Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

  2020cites this paper
• COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts

  2020cites this paper
• Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics

  2020cites this paper
• A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs

  2020cites this paper
• Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019

  2020cites this paper
• Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community

  2020cites this paper
• Liver-related effects of chronic hepatitis C antiviral treatment

  2020cites this paper
• Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy

  2020cites this paper
• SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening

  2020cites this paper
• Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).

  2020cites this paper
• COVID-19: The Immune Responses and Clinical Therapy Candidates

  2020cites this paper
• Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites

  2020cites this paper
• How can nanotechnology help to combat COVID-19? Opportunities and urgent need

  2020cites this paper
• In-line treatments and clinical initiatives to fight against COVID-19 outbreak

  2020cites this paper
• Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

  2020cites this paper
• Biocatalytic routes to anti-viral agents and their synthetic intermediates.

  2020cites this paper
• Compilation of antiviral treatments and strategies to fight fish viruses

  2020cites this paper
• Ribose Moieties Acylation and Characterization of Some Cytidine Analogs

  2020cites this paper
• A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with COPD in a Phase 1 study

  2020influential citation
• Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study

  2019influential citation
• Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.

  2019cites this paper
• Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis

  2019cites this paper
• Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: role of treatment duration

  2019cites this paper
• IMPDH inhibitors for anti-tumor therapy in tuberous sclerosis complex

  2019cites this paper
• Chromosomal instability and cytotoxicity induced by ribavirin: comparative analysis in cell lines with different drug-metabolizing profiles

  2019cites this paper
• IL-1α correlates with severity of hepatitis C virus-related liver diseases

  2018cites this paper
• Determination of antimicrobial activity of some 1,2,4-triazole derivatives

  2018cites this paper
• The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection

  2018cites this paper
• EMERGING THERAPY FOR DENGUE

  2018cites this paper
• Hepatitis B and Hepatitis C Antiviral Agents

  2018cites this paper
• Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population

  2018cites this paper
• A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry

  2017cites this paper
• Development of tools to investigate resistance of HCV genotype 3 to NS5A inhibitors

  2017cites this paper
• Antiviral Drugs for Acute Infections

  2017cites this paper
• Role of ribavirin in interferon-free therapy for the treatment of hepatitis C virus

  2017cites this paper
• Role of ribavirin in interferon-free therapy for the treatment of hepatitisC virus.

  2017cites this paper
• Acyclonucleosides bearing coplanar arylethynyltriazole nucleobases: synthesis, structural analysis, and biological evaluation

  2017cites this paper
• Host-directed therapies for bacterial and viral infections

  2017cites this paper
• Synthesis, antibacterial evaluation and survey on the thermophysical characteristics of novel medically applicable polyamides containing pharmaceutically outstanding triazole moieties

  2017cites this paper
• Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant

  2017cites this paper
• Biosynthesis of an antiviral compound using a stabilized phosphopentomutase by multipoint covalent immobilization.

  2017cites this paper
• Mécanismes d'action et de résistance des Adénovirus C au Brincidofovir

  2017cites this paper
• Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens

  2017cites this paper
• Polymerases of paramyxoviruses and pneumoviruses.

  2017cites this paper
• Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

  2016cites this paper